Volume 73, Issue 6, Pages (June 2018)

Slides:

Advertisements

Similar presentations

Volume 59, Issue 2, Pages (February 2011)

Advertisements

Volume 68, Issue 2, Pages (August 2015)

Volume 60, Issue 2, Pages (August 2011)

The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer

Volume 58, Issue 4, Pages (October 2010)

Approach to Metastatic Hormone-Sensitive Prostate Cancer

Testosterone Therapy in Men With Prostate Cancer

David Lorente, Karim Fizazi, Christopher Sweeney, Johann S. de Bono

Volume 69, Issue 5, Pages (May 2016)

Volume 68, Issue 6, Pages e129-e131 (December 2015)

Volume 61, Issue 6, Pages (June 2012)

Volume 52, Issue 5, Pages (November 2007)

Volume 60, Issue 5, Pages (November 2011)

Volume 17, Issue 2, Pages (February 2016)

Volume 53, Issue 5, Pages (May 2008)

Volume 64, Issue 4, Pages (October 2013)

Control of Prostate Cancer by Transrectal HIFU in 227 Patients

Volume 69, Issue 5, Pages (May 2016)

Volume 51, Issue 4, Pages (April 2007)

Managing Nonmetastatic Castration-resistant Prostate Cancer

Volume 68, Issue 1, Pages (July 2015)

Prostate Cancer Epidemic in Sight?

Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration- resistant Prostate Cancer in the Era of Precision Oncology Philipp.

Volume 72, Issue 5, Pages (November 2017)

Volume 62, Issue 6, Pages (December 2012)

Volume 68, Issue 1, Pages (July 2015)

Volume 65, Issue 5, Pages (May 2014)

The Importance of Transurethral Resection in Managing Patients With Urothelial Cancer in the Bladder: Proposal for a Transurethral Resection of Bladder.

Volume 68, Issue 5, Pages (November 2015)

Volume 71, Issue 1, Pages 1-3 (January 2017)

Volume 67, Issue 2, Pages (February 2015)

Intermittent Hormone Therapy: What Is Its Place in Clinical Practice?

Volume 74, Issue 1, Pages (July 2018)

Volume 66, Issue 3, Pages (September 2014)

Volume 69, Issue 6, Pages (June 2016)

Laurent Boccon-Gibod European Urology Supplements

Prostate Cancer Epidemic in Sight?

The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer

Volume 73, Issue 5, Pages (May 2018)

Volume 61, Issue 6, Pages (June 2012)

Volume 53, Issue 6, Pages (June 2008)

Leonard S. Marks, Jiaoti Huang European Urology

Current Status of Combined Radiation Therapy and Androgen Suppression in Locally Advanced Prostate Cancer: What Is the Way Forward? Michel Bolla European.

Volume 72, Issue 1, Pages (July 2017)

Volume 66, Issue 2, Pages (August 2014)

Volume 63, Issue 3, Pages (March 2013)

Shifting Paradigms for High-grade Prostatic Intraepithelial Neoplasia

Volume 71, Issue 1, Pages (January 2017)

Might Men Diagnosed with Metastatic Prostate Cancer Benefit from Definitive Treatment of the Primary Tumor? A SEER-Based Study Stephen H. Culp, Paul.

Prostate-Specific Antigen Kinetics and Outcomes in Patients with Bone Metastases from Castration-Resistant Prostate Cancer Treated with or Without Zoledronic.

Volume 71, Issue 2, Pages (February 2017)

Volume 50, Issue 5, Pages (November 2006)

CyberKnife in the Treatment of Prostate Cancer: A Revolutionary System

Bone Health in Patients With Prostate Cancer: Monitoring and Diagnosis

Volume 67, Issue 6, Pages (June 2015)

Volume 49, Issue 4, Pages (April 2006)

The 20-Yr Outcome in Patients with Well- or Moderately Differentiated Clinically Localized Prostate Cancer Diagnosed in the Pre-PSA Era: The Prognostic.

Intermittent Hormone Therapy: What Is Its Place in Clinical Practice?

Volume 71, Issue 4, Pages (April 2017)

Volume 17, Issue 2, Pages (February 2016)

Axel Heidenreich European Urology Supplements

European Urology Oncology

Volume 14, Issue 9, Pages (August 2013)

Volume 53, Issue 6, Pages (June 2008)

Prostate Radiotherapy for Metastatic Hormone-sensitive Prostate Cancer: A STOPCAP Systematic Review and Meta-analysis Sarah Burdett, Liselotte M. Boevé,

Oncoforum Urology: Prostate Cancer 2008 at a Glance

Ian W. Mills, Anna Crossland, Anup Patel, Henrikas Ramonas

Axel Heidenreich European Urology Supplements

Volume 54, Issue 1, Pages (July 2008)

Volume 51, Issue 5, Pages (May 2007)

Presentation transcript:

Volume 73, Issue 6, Pages 847-855 (June 2018) Burden of Metastatic Castrate Naive Prostate Cancer Patients, to Identify Men More Likely to Benefit from Early Docetaxel: Further Analyses of CHAARTED and GETUG- AFU15 Studies Gwenaelle Gravis, Jean-Marie Boher, Yu-Hui Chen, Glenn Liu, Karim Fizazi, Michael A. Carducci, Stephane Oudard, Florence Joly, David M. Jarrard, Michel Soulie, Mario J. Eisenberger, Muriel Habibian, Robert Dreicer, Jorge A. Garcia, Maha H.M. Hussain, Manish Kohli, Nicholas J. Vogelzang, Joel Picus, Robert DiPaola, Christopher Sweeney European Urology Volume 73, Issue 6, Pages 847-855 (June 2018) DOI: 10.1016/j.eururo.2018.02.001 Copyright © 2018 European Association of Urology Terms and Conditions

Fig. 1 Disposition of patients in the CHAARTED and GETUG-AFU15 studies. ADT=androgen deprivation therapy; D=docetaxel; HV=high volume; LV=low volume. a Including nonevaluable patients. European Urology 2018 73, 847-855DOI: (10.1016/j.eururo.2018.02.001) Copyright © 2018 European Association of Urology Terms and Conditions

Fig. 2 Overall survival in (A) patients with high-volume disease and metastases at initial diagnosis of prostate cancer, (B) patients with high-volume disease and prior local treatment (no metastases at initial diagnosis of prostate cancer), (C) patients with low-volume disease and metastases at initial diagnosis of prostate cancer, and (D) patients with low-volume disease and prior local treatment (no metastases at initial diagnosis of prostate cancer). ADT=androgen deprivation therapy; D=docetaxel. European Urology 2018 73, 847-855DOI: (10.1016/j.eururo.2018.02.001) Copyright © 2018 European Association of Urology Terms and Conditions